ArticleMedicine2019

Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma: A case report.

Hong Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.